Landfar Bio-medicine (000504.SZ) terminates the acquisition of 51% equity of Hunan Huize Biological.

Landfar Bio-medicine (000504.SZ) announcement, the company previously planned to acquire a 51% equity interest in Hunan Huize Biopharmaceutical Technology Co., Ltd. held by Cheng Ze Neng, Yimu Lin, Changsha Junhe Zhiyuan Enterprise Management Consulting Partnership (Limited Partnership), and Changsha Lufang Pharmaceutical Information Consulting Partnership (Limited Partnership). The parties to the transaction have conducted multiple negotiations and discussions on the major asset restructuring transaction plan, but they have not been able to reach a final agreement. The parties to the transaction unanimously agreed to terminate the planning of the transaction. On January 22, 2026, the company and the parties to the transaction signed a Termination Agreement of the Equity Acquisition Intent Agreement.